Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00019032 · ClinicalTrials.gov registry record · Phase 1
Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00019032: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00019032 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00019032, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating patients who have chronic lymphocytic leukemia.
Interventions
- BIOLOGICAL monoclonal antibody Mik-beta-1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 1996-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00019032
The ClinicalTrials.gov registry entry for NCT00019032 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which monoclonal antibody Mik-beta-1 is the first listed.
NCT00019032 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00019032 about?
NCT00019032 is a clinical study titled "Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia". RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating patients who have chronic lymphocytic leukemia.
What is the current status of trial NCT00019032?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 1996-03.
What interventions are being tested in trial NCT00019032?
The interventions under investigation include: monoclonal antibody Mik-beta-1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00019032?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.